Novo collaborates with Glooko to develop a range of digital health tools for diabetics

Multinational pharmaceutical firm Novo Nordisk has announced that it will collaborate with remote patient monitoring provider Glooko.

The collaboration will see the companies jointly developing a range of co-branded solutions which aim to support treatment adherence and blood glucose management for those with type 1 and type 2 diabetes.

In addition the solutions will be integrated with the digital health platform Novo has created with cognitive healthcare company IBM Watson Health. The project was developed to give diabetics and their doctors a platform to help manage their illness.

Christian Kanstrup, senior vice president, Strategy, Access & Marketing at Novo Nordisk, said: “We are excited to partner with Glooko and to take another step towards delivering digital health offerings that help people with diabetes to improve their blood glucose control.

“Working in partnerships will furthermore enhance our ability to demonstrate the real-world value of our portfolio of diabetes treatments.”

Glooko’s CEO Rick Altinger said: “Glooko’s partnership with Novo Nordisk aims to empower tens of millions of patients with digital tools to make diabetes management easier.

“We look forward to delivering jointly-branded capabilities that will enhance the collaboration between patient and healthcare professionals and enable us to provide joint offerings to people living with diabetes around the world.”